They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more

The team behind CuraSen sold their previous drug development company for up to $1.25 billion.

Source: bizjournals.com Health Care:Biotechnology headlines - October 17, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news